The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae
Open Access
- 1 December 2013
- journal article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. 6, 235-240
Abstract
The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black Novexel, Romainville, France Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae was investigated by ampC messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as ampC inducers, whereas avibactam was found to exert no effect on ampC expression. Thus, avibactam is unlikely to diminish the activity of any partner β-lactam antibiotic against AmpC-producing organisms. Keywords: β-lactamase, ampC, induction, NXL104, avibactamKeywords
This publication has 18 references indexed in Scilit:
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009
- AmpC β-LactamasesClinical Microbiology Reviews, 2009
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemasesJournal of Antimicrobial Chemotherapy, 2008
- Resistance to ?-lactam antibioticsCellular and Molecular Life Sciences, 2004
- In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitorJournal of Antimicrobial Chemotherapy, 2004
- Important and Emerging β-Lactamase-mediated Resistances in Hospital-based Pathogens: The Amp C EnzymesDiagnostic Microbiology and Infectious Disease, 1998
- In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989